UNITED THERAPEUTICS Corp
Close on Oct 19, 2026
- Market cap
- $24.88B
- P/E (TTM)
- 19.4
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $783.30M | $7.27 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $781.50M | $5.82 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | Before market open | $790.20M | $7.70 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | Before market open | $799.50M | $7.16 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | Before market open | $798.60M | $6.41 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | Before market open | $794.40M | $6.63 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | Before market open | $735.90M | $6.19 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | Before market open | $748.90M | $6.39 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | Before market open | $714.90M | $5.85 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 21, 2024 | Before market open | – | – | – |
Press releases
Announcements United Therapeutics filed with the SEC
Settlement Agreement (this “ Agreement ”) is made and entered into as of the last date of signature of this Agreement
Other events · EX-99.1 to Form 8-K
Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corporation Announces Appointment of Victor Dzau to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
United Therapeutics Corporation Announces TETON-1 Pivotal
Other events · EX-99.1 to Form 8-K
$2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
United Therapeutics Corporation Announces Ralinepag
Regulation FD disclosure · EX-99.1 to Form 8-K
Phase 3 ADVANCE OUTCOMES Results
Regulation FD disclosure · EX-99.2 to Form 8-K
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
Other events · EX-99.1 to Form 8-K
Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
MIROKIDNEY®, MIROLIVERELAP®, ORENITRAM®, REMODULIN®, TYVASO®, and TYVASO DPI® are registered trademarks of United Therapeutics Corporation and/or its subsidiaries.
Regulation FD disclosure · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Corporation Announces Election of Jan Malcolm to its Board of Directors
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
United Therapeutics Corporation Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
United Therapeutics Wins Appeal in
Other events · EX-99.1 to Form 8-K
FIRST QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
UNITED THERAPEUTICS CORPORATION REPORTS FOURTH QUARTER
Results of operations · EX-99.1 to Form 8-K
UTHR: A Public Benefit Corporation | January 2023 | 1 United Therapeutics: Enabling Inspiration J.P. Morgan 41 st Annual Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
UNITED THERAPEUTICS ANNOUNCES FIRST PATIENT
Other events · EX-99.1 to Form 8-K
United Therapeutics Prevails in Dry Powder Inhaler
Other events · EX-99.1 to Form 8-K
Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
United Therapeutics Announces FDA Approval of
Other events · EX-99.1 to Form 8-K
First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
United Therapeutics Corporation Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Provides an Update on the Progress
Other events · EX-99.1 to Form 8-K